We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Antibody Inhibits Breast Cancer Growth in Mice

By Biotechdaily staff writers
Posted on 29 Dec 2006
A monoclonal antibody has been shown to extend considerably the survival of mice with human breast-cancer tumors and to inhibit tumor metastasis to the lungs in the animals by more than 50%.

The antibody, called JAA-F11, targets a specific disaccharide, an antigen known as TF-Ag, which helps in the adhesion and spread of certain cancer cells. More...
Whereas the antibody did not kill the cancer cells, it blocked stages of cancer-cell growth that allow the cells to attach to organ tissue, the study demonstrated. The study's findings were published in the November 2006 issue of the journal Neoplasia.

Mice with breast-cancer tumors that received the antibody had an average survival time of 72 days, compared to 57 days for the mice that did not receive JAA-F11, the study found. Furthermore, exposing cultures of tumor cells to the antibody suppressed cell growth by a statistically significant 16%.

Kate Rittenhouse-Olson, Ph.D., associate professor of clinical and laboratory sciences in the University at Buffalo School of Medicine and Biomedical Sciences (Buffalo, NY, USA), was the senior investigator of the study. "This antibody binds with a carbohydrate on the tumor cell surface that is involved in adhesion of the cell during the metastatic process,” said Dr. Rittenhouse-Olson. "Not only would drugs attached to the antibody JAA-F11 bind to the tumor cell surface to direct their cytotoxic effect, but the binding of the antibody itself would block the cell from metastasizing.”

The antibody was evaluated utilizing in vitro models of tumor cell growth in assays to determine its ability to damage or kill cells (cytotoxicity) in various models of cancer metastasis, and finally, in mice with metastatic breast cancer. "In addition to providing a survival advantage,” remarked Dr. Rittenhouse-Olson, "JAA-F11 immunotherapy reduced the metastatic tumor burden significantly, reflected by both a dramatic decline in the overall incidence of spontaneous metastasis to the lung--88% to 47%--and fewer macroscopic metastatic lesions.”

The investigators currently are determining if JAA-F11 could increase the effectiveness of existing cancer drugs, according to Dr. Rittenhouse-Olson, as well as evaluating the possibility of using the antibody as a vehicle for the targeted delivery of drugs to aid cancer diagnosis and therapy.



Related Links:
University at Buffalo School of Medicine and Biomedical Sciences

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.